The global autoinjector devices market is projected to reach USD 1.7 billion in 2028 from USD 0.9 billion in 2023, growing at a CAGR of 14.0%. Whereas, the autoinjector finished formulations market is projected to reach USD 136.5 billion in 2028 from USD 59.6 billion in 2023, growing a CAGR of 18.0%. The key factors driving the growth of the global autoinjectors market are the growing availability of generic versions of autoinjectors, favorable government reimbursement scenario among others.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724
Rheumatoid Arthritis subsegment accounted for the largest share of the autoinjectors market by therapy area
Among the therapy area, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapy areas. In 2023, the rheumatoid arthritis segment accounted for the largest share of the autoinjectors market by therapy area.
Key Market Players
The market for autoinjectors is consolidated, with key players strategizing to capture majority of the market. Prominent players in the market are Becton, Dickinson and Company (BD) (US), Ypsomed Holding AG (Switzerland), SHL Medical (Switzerland), West Pharmaceutical Services, Inc. (US), Recipharm AB (Sweden), Haselmeier GmbH (Germany), Owen Mumford Ltd. (UK), Gerreshiemer AG (Germany), Philip-Medisize, LLC (US), Oval Medical Technologies Ltd. (UK), Solteam Incorporation Co., Ltd. (China), Elcam Drug Delivery Devices (E3D) (Israel), Antares Pharma, Inc. (US), Jabil, Inc. (US), and the some of the major market players for finished formulations covered in this chapter include AbbVie Inc. (US), Amgen Inc. (US), Eli Lilly and Company (US), Novartis AG (Switzerland), Merck KGaA (Germany), Viatris Inc. (US), and Biogen (US).
Becton, Dickinson and Company (BD)
BD is the leading players in the global autoinjector devices market. The company offers self-injection device systems. BD is focused on strategies such as innovation, expansions, and partnerships to enhance its presence in the autoinjectors market. For instance, the company has successfully conducted human clinical trials for the BD Libertas wearable injector.
Ypsomed Holding AG
Ypsomed Holding AG is one of the leading players in the global autoinjector devices market. Ypsomed offers self-injection device systems along with infusion systems. The has a strong geographic presence along with patient-centric autoinjector products are contributing to its growing market share.
AbbVie Inc.
AbbVie is one of the leading players in the Autoinjectors finished formulations market. The company’s blockbuster product is Humira Pen. AbbVie has a strong supply chain globally with wholesalers, distributors, government agencies, healthcare facilities, specialty pharmacies, and independent retailers marketing its products worldwide.
Amgen Inc.
Amgen focuses on discovery, development, manufacturing, and marketing of innovative human therapeutics. The company is engaged in the production of innovative medicines, expanding its global geographic reach, enhancing next-generation biomanufacturing, improving drug delivery systems, and offering branded biosimilars.
Browse Complete Report along with TOC @ https://www.marketsandmarkets.com/Market-Reports/autoinjector-market-173991724.html
Europe: The second-largest region in the autoinjectors market.
The European autoinjectors market is the second-largest autoinjectors market globally, mainly due to factors such as presence of a large geriatric population in the region and the improving reimbursement and regulatory scenario. The presence of large geriatric population in the region is expected to increase the prevalence of chronic diseases leading consequently leading to growing adoption of autoinjectors for treatment of these disease.
Recent Developments:
- In May 2023, SHL Medical and MoonLake Immunotherapeutics collaborated to develop the sonelokimab autoinjector. SHL Medical's Molly autoinjector technology will be utilized for the clinical and potential commercial supply of MoonLake's Nanobody sonelokimab.
- In October 2022, BD partnered with Biocorp for Biocorp's Injay technology, which adds connectivity to prefilled syringes. It is expected to aid BD in tracking adherence to self-administered injectable drugs.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=173991724
About MarketsandMarkets™:
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
